Whilst our work unveils a potential therapeutic role for Tonabersat in suppression of key inflammatory pathways and paracrine mediated cell crosstalk, future studies are now required to determine the efficacy of Tonabersat or alternative Cx43 hemichannel blockers in models of DKD, notably those where full renal function can be assessed. The gene discussed is GJA1; the disease is diabetic kidney disease.